Moreover, because of the complexity of TGF-β signaling role and crosstalk with other factors (such as immunochemotactic and angiogenic agents) in the derived tumor microenvironment, designing therapeutic intervention strategies for targeting tumors in this field, should be very carefully. This evidence concerns the gene TGFB1 and neoplasm.